Rare AutoImmune SElf-management Programme Development
NCT06642870 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 360
Last updated 2024-10-15
Summary
The rare autoimmune rheumatic diseases (RAIRDs) are life-long multi-system diseases that are life or organ threatening. RAIRDs can impair quality of life similar to chronic diseases such as heart failure. The aim of the study is to explore content and structure of a support programme for people with RAIRDs in focus groups and survey meetings.
Conditions
- Systemic Lupus Erthematosus
- Systemic Vasculitis
- Inflammatory Myositis
- Systemic Sclerosis (SSc)
- ANCA Associated Vasculitis (AAV)
- Sjogren Syndrome
Interventions
- OTHER
-
Non-interventional study
The study will consist of focus groups and a large scale patient survey
Sponsors & Collaborators
-
University of Leeds
collaborator OTHER -
University of the West of England
lead OTHER
Principal Investigators
-
Joanna Robson · University of the West of England
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2024-10-31
- Primary Completion
- 2025-10-31
- Completion
- 2026-04-30
Countries
- United Kingdom
Study Locations
More Related Trials
-
Immune Mediators and Metabolites to Stratify Systemic Lupus Erythematosus Patients at High Risk of Cardio Vascular Diseases
NCT04276701 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
Occupational and Environmental Causes of Autoimmune Diseases
NCT07000903 ·Status: COMPLETED ·Phase: NA
-
Study of the Role of Soluble Forms of RAGE (sRAGE/esRAGE) as Diagnostic and Prognostic Biomarkers of Systemic Lupus Erythematosus.
NCT02891213 ·Status: UNKNOWN
-
Safety and Efficacy of Universal CD19-targeting CAR-γδT Cells in Refractory Autoimmune Diseases
NCT06828042 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Comparison of the Efficacy of Two Rituximab Treatment Regimens in Patients With Lupus Nephropathy
NCT01765842 ·Status: TERMINATED ·Phase: PHASE3
-
Subgrouping SLE - a New Approach to Understand the Pathogenesis and Improve Treatment
NCT07102030 ·Status: RECRUITING
-
Clinical Autoinflammatory Disease Cohort
NCT07126145 ·Status: NOT_YET_RECRUITING
-
Prevalence of Peripheral Vascular Diseases and Presentation in Patients With Autoimmune Diseases
NCT06169865 ·Status: RECRUITING
-
Cardiology Prevention in Systemic Lupus Erythematosus (SLE)
NCT00610805 ·Status: WITHDRAWN ·Phase: NA
-
Ultrasonic COmparison of Salivary Glands in Autoimmune Diseases (COUGAR)
NCT06680310 ·Status: NOT_YET_RECRUITING
-
Molecular Mechanisms Characteristics in Systemic Lupus Erythematous Autoimmune Disease
NCT02270710 ·Status: WITHDRAWN
-
Immunome Project Consortium for Autoinflammatory Disorders
NCT03919110 ·Status: COMPLETED
-
This Project Aims to Understand the Needs of Rheumatologists and Other Specialties in the Care of Patients With SLE
NCT06698900 ·Status: COMPLETED
-
Detection of Annexin A2 in Systemic Lupus Erythematosus
NCT03031925 ·Status: COMPLETED ·Phase: NA
-
The Role of Anifrolumab in Improving Markers of Vascular Risk in Patients With Systemic Lupus Erythematosus (SLE) - IFN-CVD
NCT05440422 ·Status: RECRUITING ·Phase: PHASE2
-
Anti-CD20 Antibodies for Treatment of SLE-PAH
NCT05828147 ·Status: RECRUITING ·Phase: PHASE4
-
Determining the Responses and Impact of Rituximab-instigated Cell Depletion on T Cells in People With SLE
NCT01702038 ·Status: WITHDRAWN ·Phase: PHASE2
-
Improving the Assessment of SLE Disease Activity
NCT03144063 ·Status: COMPLETED
-
Open-label Study of Epratuzumab in Serologically-positive Systemic Lupus Erythematosus Patients With Active Disease
NCT00660881 ·Status: COMPLETED ·Phase: PHASE2
-
Renal Assessment for Early Detection of Renal Impairment in Systemic Sclerosis and Systemic Lupus Erythematosus Patients
NCT06287125 ·Status: NOT_YET_RECRUITING
-
Autotaxin as Abiomarker in Systemic Lupus Erythematosus Patients
NCT06063668 ·Status: NOT_YET_RECRUITING
-
An Observational Study of Patients With Autoimmune Disease
NCT05842824 ·Status: NOT_YET_RECRUITING
-
Rituximab Objective Outcome Measures Trial in SLE
NCT03054259 ·Status: UNKNOWN ·Phase: PHASE2
-
Rheumatology Patient Registry and Biorepository
NCT04402086 ·Status: RECRUITING
-
LUMIER² Study : LUpus Molecular Immunomonitoring to Evaluate the Risk of Relapse
NCT02811094 ·Status: TERMINATED ·Phase: NA